Hubungan Hemoglobin Terglikosilasi (HbA1c) Dengan Risiko Kardiovaskular Pada Pasien Diabetes Mellitus

Authors

  • Hadian Widyatmojo Bagian Patologi Klinik Fakultas Kedokteran Universitas Diponegoro, Semarang, Indonesia
  • Lisyani Budipradigda Suromo Bagian Patologi Klinik Fakultas Kedokteran Universitas Diponegoro/ RSUP Dr. Kariadi, Indonesia

DOI:

https://doi.org/10.36408/mhjcm.v7i2.500

Keywords:

DM, HbA1c, Skor risiko Interheart

Abstract

Latar belakang : Diabetes Mellitus (DM) dengan kondisi hiperglikemik kronik  dapat mengakibatkan gangguan sistem kardiovaskular dan peningkatan  mortalitas. Hemoglobin terglikosilasi (HbA1c) merupakan salah satu parameter untuk pengendalian DM. Tujuan penelitian untuk membuktikan adanya hubungan antara kadar HbA1c serum dengan risiko kardiovaskular pada pasien DM.

Metode : Penelitian belah lintang dilakukan pada 42 penderita DM yang dirawat di RSUP Dr. Kariadi Semarang periode Agustus - September 2017. Diagnosis DM didapatkan melalui rekam medis. Dilakukan pemeriksaan HbA1c dan dinilai faktor risiko yang terdapat pada rekam medis menggunakan skor interheart (IHR). Analisa statistik menggunakan uji korelasi Spearman.

Hasil : Terdapat hubungan antara HbA1c dengan skor IHR dengan nilai r=0,887, p=0,001. Pasien dengan kategori risiko kardiovaskular tinggi memiliki nilai HbA1c dengan rerata 10,12 ± 2,29, skor kategori sedang 6,62 ± 1,67 dan skor kategori rendah 5,75 ± 0,78.

Simpulan :Terdapat hubungan positif kuat antara HbA1c dengan risiko kardiovaskular pada pasien DM. Perlu dilakukan penelitian prospektif dengan sampel yang lebih besar.

Kata kunci

DM, HbA1c, Skor risiko Interheart

Downloads

Download data is not yet available.

References

World Health Organization. Part 1: Diagnosis and Classification of Diabetes Mellitus. WHO/NCD/NCS/99.2 ed. Geneva: World Health Organization; 1999. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications.

World Health Organization. Use of Glycated Hemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. WHO/NMH/CHP/CPM/11.1 ed. Geneva: World Health Organization; 2011. Abbreviated report of a WHO consultation.

PERKENI. Konsensus pengendalian dan pencegahan diabetes melitus Tipe 2 di Indonesia. Jakarta: PERKENI; 2015.

Masharani U, German M. Pancreatic hormones and Diabetes Mellius. In: Gardner D, Shoback D, Editors. Greenspan’s Basic & Clinical Endocrinology. 9th Ed. China: Mcgraw-Hill; 2011. p.573-644.

Suryaatmadja M. Pemeriksaan kadar HbA1c untuk diagnosis prediabetes. In : Pendidikan Berkesinambungan Patologi Klinik 2013. Jakarta : FKUI;2013. p.57-69.

Pramudiati M. Glycated Hemoglobin (A1c) dan Glycated Albumin sebagai prediktor komplikasi diabetes. In : JOGLOSEMAR V Menuju pelayanan laboratorium yang berkelas dunia. Solo : CPD CPLM Joglosemar V; 2013. p.217-21.

Kementerian Kesehatan RI. Keputusan Menteri Kesehatan Republik Indonesia Nomor 1792/MENKES/SK/XII/2010 tentang Pedoman pemeriksaan Kimia Klinik. 2009.

McGorian C, Yusuf S, Islam S, Jung H, et al. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. European heart journal 2011; 5(1): 581-1400.

Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Journal of Internal Medicine 2010; 268 (3): 471–82.

Arnold L, Hoy W, Sharma S, Wang Z. The Association between HbA1c and Cardiovascular disease markers in a remote indigenous Australian Community with and without diabetes. Journal of Diabetes Research 2016: 1-8.

Beckman JA, Creager MA, Libby P. Diabetes And atherosclerosis:epidemiology, pathophysiology, and management. JAMA 2002; 287(1):2570-81.

Sheetz MJ, King GL. Molecular understanding of hypergycaemia’s adverse effects for diabetic complications. JAMA 2002; 288(1) :2579-88.

Additional Files

Published

2020-11-19

How to Cite

1.
Widyatmojo H, Suromo LB. Hubungan Hemoglobin Terglikosilasi (HbA1c) Dengan Risiko Kardiovaskular Pada Pasien Diabetes Mellitus. Medica Hospitalia J. Clin. Med. [Internet]. 2020 Nov. 19 [cited 2024 Apr. 16];7(2):379-83. Available from: http://medicahospitalia.rskariadi.co.id/medicahospitalia/index.php/mh/article/view/500

Issue

Vol. 7 No. 2 (2020): Med Hosp; Nov 2020

Section

Original Article

Citation Check

License

Copyright (c) 2020 Medica Hospitalia : Journal of Clinical Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.